Clinical Trials

  Circassia, a specialty biopharmaceutical company, has announced positive results from Phase II clinical trial of ragweed allergy therapy.   According to the study, patients with more severe symptoms achieved a greater improvement following treatment with...

PhaseBio Pharmaceuticals, a biotechnology company, has initiated Phase I clinical study with its novel compound, Vasomera (PB1046), in patients with Stage 1 and 2 essential hypertension. The primary objective of the placebo-controlled study is...

TxCell SA, a biotechnology company, has announced positive immuno-monitoring results of the Phase I/II study in Crohn's disease with Ovasave. The open label, multicenter CATS1 study included 20 patients with severe chronic active Crohn's...

Galena Biopharma has initiated Phase III trial for NeuVax (E75 peptide plus GM-CSF) vaccine in HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence. The Prevention of Recurrence in...

Genta's Tesetaxel has demonstrated efficacy in the Phase 2b, confirmatory clinical trial, designed to evaluate the drug in patients with advanced gastric cancer. Tesetaxel is a novel, orally absorbed taxane that has been evaluated...

Sanofi and Regeneron Pharmaceuticals, Inc. announced positive preliminary results from the Phase 2 study program in which patients with elevated low-density lipoprotein cholesterol (LDL-C) were treated with REGN727/SAR236553. REGN727/SAR236553 is a novel, high-affinity, subcutaneously administered, fully-human...

TxCell SA, a biotechnology company developing Treg cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical needs, announces today the presentation of final positive results of the phase I/II study in Crohn’s disease (CATS-1)...